Janssen’s Daniel de Schryver tells us why it’s time to give patients a permanent seat at the table and improve health outcomes through patient-pharma dialogue.
Pharmaceutical companies often struggle to actively involve patients in the design phase of clinical trials but doing so can have huge benefits for the sustainability and success of researc
COVID-19 has sparked a flurry of research and discoveries are being made at an unprecedented rate – but patient participation cannot and should not be left behind in the rush, say leading v
Ahead of her appearance at eyeforpharma Barcelona, Merck’s director of patient advocacy and strategic partnerships, Vanessa Pott, tells us how the company is approaching patient centric
Improving clinical trial recruitment has long been a priority for pharma, but despite having a plethora of new innovations at their disposal, along with a sincere commitment to patient cent
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.